Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume Increase - Here's Why

Key Points

• Trading volume rose 28% as mid-day volume climbed to 4,097 shares and the stock last traded at $23.85 versus the prior close of $22.34.
• Strong analyst optimism: the consensus rating is "Buy" with an average price target of $46.67, driven by recent Buy/Strong-Buy initiations and reiterations from firms including Deutsche Bank, BTIG and China Intl Cap.
• Clinical-stage biopharma with ongoing losses: Ascentage develops apoptosis-targeting drugs (e.g., APG-2575, APG-115) but reported a ($0.52) EPS last quarter and is forecast to post about -1.09 EPS for the year.

Shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) saw an uptick in trading volume on Friday . 4,097 shares were traded during mid-day trading, an increase of 28% from the previous session's volume of 3,212 shares.The stock last traded at $23.8490 and had previously closed at $22.34.

Wall Street Analyst Weigh In

Several research firms have weighed in on AAPG. Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a research report on Friday. They set a "buy" rating and a $40.00 price objective on the stock. BTIG Research restated a "buy" rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. China Intl Cap raised shares of Ascentage Pharma Group International to a "strong-buy" rating in a research report on Monday, April 6th. Finally, Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They issued a "buy" rating and a $48.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company's stock. According to MarketBeat.com, Ascentage Pharma Group International currently has a consensus rating of "Buy" and an average target price of $46.67.

Ascentage Pharma Group International Price Performance

The company has a 50 day simple moving average of $24.43 and a 200 day simple moving average of $28.16. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79.

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million for the quarter. On average, sell-side analysts predict that Ascentage Pharma Group International - Unsponsored ADR will post -1.09 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at $96,000. ABC Arbitrage SA acquired a new position in Ascentage Pharma Group International in the 3rd quarter worth about $204,000. Citadel Advisors LLC acquired a new position in Ascentage Pharma Group International in the 3rd quarter worth about $383,000. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International in the second quarter valued at about $391,000. Finally, XY Capital Ltd raised its position in Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company's stock valued at $707,000 after purchasing an additional 12,530 shares during the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.